Publisher
Japanese Society on Thrombosis and Hemostasis
Reference9 articles.
1. 1) Broome C: Efgartigimod alpha for the treatment of primary immune thrombocytopenia. Ther Adv Hematol 14: 1–11, 2023.
2. 2) Broome CM, McDonald V, Miyakawa Y, et al.: Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): A multicenter, randomized, placebo-controlled, phase 3 trial. Lancet 402: 1648–1659, 2023.
3. 3) Pyzik M, Kozicky LK, Gandhi AK, et al.: The therapeutic age of the neonatal Fc receptor. Nat Rev Immunol 23: 415–432, 2023.
4. 4) Howard Jr JF, Bril V, Vu T, et al.: Safety, efficacy, and torelability of efgartigimiod in patients with generalized myasthenia gravis (ADAPT): A multicenter, randomized, placebo-controlled, phase 3 trial. Lancet Neurol 20: 526–536, 2021.
5. 5) Yunce M, Katyal N, Monis GF, et al.: Neonatal Fc receptor blockade as emerging therapy in diseases with plasma exchange indications. J Clin Apher 38: 632–640, 2023.